Hostname: page-component-77c89778f8-m8s7h Total loading time: 0 Render date: 2024-07-20T22:01:54.260Z Has data issue: false hasContentIssue false
  • English
  • Français

Application of the IDSA Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients: Impact on Reducing the Use of Glycopeptides

Published online by Cambridge University Press:  02 January 2015

Marcio Nucci ,
Marianne Landau ,
Fernanda Silveira ,
Nelson Spector  and
Wolmar Pulcheri
Marcio Nucci*
Affiliation:
University Hospital, Universidade Federal do Rio de Janeiro, Brazil
Marianne Landau
Affiliation:
University Hospital, Universidade Federal do Rio de Janeiro, Brazil
Fernanda Silveira
Affiliation:
University Hospital, Universidade Federal do Rio de Janeiro, Brazil
Nelson Spector
Affiliation:
University Hospital, Universidade Federal do Rio de Janeiro, Brazil
Wolmar Pulcheri
Affiliation:
University Hospital, Universidade Federal do Rio de Janeiro, Brazil
*
Servico de Hematologia, Hospital Universitdrio Clementino Fraga Filho, Av. Brigadeiro Trompovsky s/n CEP 21941-590 Rio de Janeiro, Brasil
Get access Rights & Permissions [Opens in a new window]

Abstract

We evaluated the impact of applying the Infectious Diseases Society of America guidelines for febrile neutropenic patients in reducing the use of glycopeptides. Forty-five prior episodes of febrile neutropenia were compared to 97 episodes seen after application of the guidelines. Glycopeptide use was reduced from 73% to 43% of episodes (P=.0008), without changes in outcome.

Type
Concise Communications
Information
Infection Control & Hospital Epidemiology , Volume 22 , Issue 10 , October 2001 , pp. 651 - 653
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2001

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Tornieporth, NG, Roberts, RB, John, J, Hafner, A, Riley, LW. Risk factors associated with vancomycin-resistant Enterococcus faecium infection or colonization in 145 matched case patients and control patients. Clin Infect Dis 1996;23:767–772.Google Scholar
2. Veach, LA, Pfaller, MA, Barret, M, Koontz, FP, Wenzel, RP. Vancomycin resistance in Staphylococcus haemolyticus causing colonization and bloodstream infection. J Clin Microbiol 1990;28:2004–2008.CrossRefGoogle ScholarPubMed
3. Wenzel, RP, Edmond, MB. Vancomycin-resistant Staphylococcus aureus— infection control considerations. Clin Infect Dis 1998;27:245–251.CrossRefGoogle ScholarPubMed
4. Richet, HM, Andermont, A, Tancrede, C, Pico, JL, Jarvis, WR. Risk factors for candidemia in patients with acute lymphocytic leukemia. Rev Infect Dis 1991;19:19–36.Google Scholar
5. Hughes, W, Armstrong, D, Bodey, GP, Brown, AE, Edwards, JE, Feld, R, et al. 1977 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis 1997;25:551–573.Google Scholar
6. Classen, DC, Burke, JP, Ford, CD, Evershed, S, Aloia, MR, Wilfahrt, JR. Streptococcus mitis sepsis in bone marrow transplant patients receiving oral antimicrobial prophylaxis. Am J Med 1990;89:441–446.Google Scholar
7. Cruciani, M, Rampazzo, R, Malena, M, Lazzarini, L, Todeschini, G, Messori, A, et al. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis 1996;23:795–805.Google Scholar
8. Engels, EA, Lau, J, Barza, M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol 1998;16:1179–1187.Google Scholar